| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors
|
Peyraud, F.
|
|
|
33 |
10 |
p. 1041-1051
|
artikel
|
| 2 |
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS G12D-mutated non-small-cell lung cancer
|
Ricciuti, B.
|
|
|
33 |
10 |
p. 1029-1040
|
artikel
|
| 3 |
Editorial Board
|
|
|
|
33 |
10 |
p. iii
|
artikel
|
| 4 |
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial
|
Frenel, J.S.
|
|
|
33 |
10 |
p. 1021-1028
|
artikel
|
| 5 |
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Lordick, F.
|
|
|
33 |
10 |
p. 1005-1020
|
artikel
|
| 6 |
Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
|
Kristeleit, R.S.
|
|
|
33 |
10 |
p. 989-991
|
artikel
|
| 7 |
Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer
|
Brunet, M.
|
|
|
33 |
10 |
p. 1084-1085
|
artikel
|
| 8 |
Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 ☆
|
André, T.
|
|
|
33 |
10 |
p. 1052-1060
|
artikel
|
| 9 |
Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
|
Obermannová, R.
|
|
|
33 |
10 |
p. 992-1004
|
artikel
|
| 10 |
Reply to the Letter to the Editor ‘Does the result of a small-scale phase II study of nivolumab for cancer of unknown primary justify regulatory approval?’ by Y. Sasaki; E. Sato & C. Sakaguchi
|
Tanizaki, J.
|
|
|
33 |
10 |
p. 1083-1084
|
artikel
|
| 11 |
Risk-adapted modulation through deintensification of cancer treatments: an ESMO classification
|
Hannoun-Levi, J.-M.
|
|
|
33 |
10 |
p. 1088
|
artikel
|
| 12 |
Single cell heterogeneity and evolution of breast cancer bone metastasis and organoids reveals therapeutic targets for precision medicine
|
Ding, K.
|
|
|
33 |
10 |
p. 1085-1088
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
33 |
10 |
p. i-ii
|
artikel
|
| 14 |
Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study ☆
|
Groenland, S.L.
|
|
|
33 |
10 |
p. 1071-1082
|
artikel
|
| 15 |
Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
|
Lian, B.
|
|
|
33 |
10 |
p. 1061-1070
|
artikel
|
Tijdschrift beschrijving